What Collegium Pharmaceutical’s Valuation Trend Indicates
Collegium Pharmaceutical’s net loss decreased from $21.12 million in the second quarter of 2017 to $13.06 million in the second quarter of 2018, which translated into a net loss per share of $0.40 in the second quarter as compared with a net loss per share of $0.72 in the second quarter of 2017. In August 2018, of the total eight analysts covering Collegium Pharmaceutical, three analysts have given the stock a “strong buy” rating, and five analysts have given Collegium Pharmaceutical a “buy” rating. The mean rating for Collegium Pharmaceutical stock is 1.63 with a target price of $31.67.